Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd has completed a pivotal phase of its Phase I/II clinical trial by successfully dosing 6 subjects with a high-dose, rapid infusion of its synthetic anti-infective RECCE® 327, targeting UTI/Urosepsis treatments. Preliminary results of this cohort are imminent, as an Independent Safety Committee undertakes data review, marking a significant step towards a Phase II efficacy trial. The trial aims to establish RECCE® 327 as an effective, fast-infusion frontline treatment for UTI/Urosepsis, promising to improve patient care and reduce healthcare burdens.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
